In early August, an article at the Brighter Side discussed a 2022 study suggesting that NAD+ booster Nicotinamide Riboside “NR” (FAQs) (Life Changing Anecdotes) may impact metabolic pathways involved in neurodegenerative diseases like Alzheimer’s. We covered the principal investigator on this study, Dr. Martens, and the results of his study here. So, what studies do we now have demonstrating NR might be helpful for Alzheimer’s patients?

  1. NAD+supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency (2018) (Link)
  2. NAD+supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS–STING (2021) (Link)
  3. Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model (2022) (Link)
  4. Human fibroblasts from sporadic Alzheimer’s disease (AD) patients show mitochondrial alterations and lysosome dysfunction (2024) (Link)

Related:

  • FAQs on the Potential for Nicotinamide Riboside (NR) in Alzheimer’s Patients (Link)
  • Nicotinamide Riboside “NR” (FAQs) (Consumer Reviews)

FOLLOW us on Twitter @RaisingNAD